NTNG1

Summary

NTNG1 (netrin G1, HGNC:23319) is a protein-coding gene on chromosome 1p13.3, encoding Netrin-G1 (Q9Y2I2). Involved in controlling patterning and neuronal circuit formation at the laminar, cellular, subcellular and synaptic levels.

This gene encodes a preproprotein that is processed into a secreted protein containing eukaroytic growth factor (EGF)-like domains. This protein acts to guide axon growth during neuronal development. Polymorphisms in this gene may be associated with schizophrenia. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 22854 — RefSeq curated summary.

At a glance

• Gene–disease (curated): atypical Rett syndrome (Supportive, GenCC) — +2 more curated relationships
• Clinical variants (ClinVar): 85 total
• MANE Select transcript: NM_001113226

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23319
Approved symbol	NTNG1
Name	netrin G1
Location	1p13.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0976, Lmnt1, NetG1, NetrinG1
Ensembl gene	ENSG00000162631
Ensembl biotype	protein_coding
OMIM	608818
Entrez	22854

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 8 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000294649, ENST00000370065, ENST00000370066, ENST00000370067, ENST00000370068, ENST00000370073, ENST00000370074, ENST00000370076, ENST00000462149, ENST00000477948, ENST00000901085, ENST00000945945

RefSeq mRNA: 11 — MANE Select: NM_001113226 NM_001113226, NM_001113228, NM_001312688, NM_001330665, NM_001372166, NM_001372167, NM_001372168, NM_001372169, NM_001372170, NM_001372171, NM_014917

CCDS: CCDS30785, CCDS44179, CCDS44180, CCDS81354

Canonical transcript exons

ENST00000370068 — 8 exons

Exon	Start	End
ENSE00001451652	107141039	107141140
ENSE00001451655	107480611	107484923
ENSE00001451660	107436665	107436799
ENSE00001451661	107430750	107430917
ENSE00001451666	107407682	107407708
ENSE00003471810	107324282	107324922
ENSE00003594347	107148069	107148839
ENSE00003599329	107395154	107395326

Expression profiles

Bgee: expression breadth ubiquitous, 198 present calls, max score 96.63.

FANTOM5 (CAGE): breadth broad, TPM avg 5.0538 / max 373.1940, expressed in 797 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4316	2.9347	663
4317	0.9556	327
4324	0.7606	392
4322	0.6288	248
4318	0.2932	118
201600	0.2545	145
4320	0.2520	61
201599	0.2406	105
4321	0.1779	99
4319	0.1639	47

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	96.63	gold quality
buccal mucosa cell	CL:0002336	89.10	gold quality
Brodmann (1909) area 23	UBERON:0013554	87.56	gold quality
middle temporal gyrus	UBERON:0002771	87.27	gold quality
primary visual cortex	UBERON:0002436	86.51	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.01	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.62	gold quality
germinal epithelium of ovary	UBERON:0001304	82.43	gold quality
occipital lobe	UBERON:0002021	81.46	gold quality
entorhinal cortex	UBERON:0002728	80.79	gold quality
dorsal plus ventral thalamus	UBERON:0001897	80.56	gold quality
superior frontal gyrus	UBERON:0002661	78.02	gold quality
ventricular zone	UBERON:0003053	77.86	gold quality
prefrontal cortex	UBERON:0000451	77.70	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	77.43	gold quality
parietal pleura	UBERON:0002400	77.27	gold quality
right frontal lobe	UBERON:0002810	76.98	gold quality
frontal cortex	UBERON:0001870	76.84	gold quality
hypothalamus	UBERON:0001898	76.71	gold quality
neocortex	UBERON:0001950	76.55	gold quality
postcentral gyrus	UBERON:0002581	76.32	gold quality
ganglionic eminence	UBERON:0004023	75.96	gold quality
endothelial cell	CL:0000115	75.80	silver quality
Brodmann (1909) area 9	UBERON:0013540	75.74	gold quality
cerebral cortex	UBERON:0000956	75.39	gold quality
cingulate cortex	UBERON:0003027	75.32	gold quality
anterior cingulate cortex	UBERON:0009835	75.08	gold quality
parietal lobe	UBERON:0001872	74.84	gold quality
temporal lobe	UBERON:0001871	74.35	gold quality
sural nerve	UBERON:0015488	73.71	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	56.43
E-CURD-119	yes	33.78
E-ANND-3	yes	6.93

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

197 targeting NTNG1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-7-1-3P	99.91	71.53	4384

Literature-anchored findings (GeneRIF, showing 17)

• Netrin-G1 is an important part of the NGL-1 receptor and functions to promote the outgrowth of dorsal thalamic axons. (PMID:14595443)
• findings suggest that netrin G1 or a nearby gene may contribute to overall genetic risk for schizophrenia (PMID:15508520)
• Specific haplotypes encompassing alternatively spliced exons of NTNG1 were associated with schizophrenia, and concordantly, messenger ribonucleic acid isoform expression was significantly different between schizophrenic and control brains. (PMID:15705354)
• Sequence analysis of the cloned junction fragment indicated that on chromosome 1 the predominantly brain-expressed Netrin G1 (NTNG1) gene is disrupted, whereas on chromosome 7 there was no indication for a truncated gene (PMID:15870826)
• NTNG1 may use alternative splicing to diversify its function in a developmentally and tissue-specific manner. (PMID:15901489)
• Mutations in the NTNG1 gene appear to be a rare cause of Rett syndrome but NTNG1 function demands further investigation in relation to the central nervous system pathophysiology of the disorder. (PMID:16502428)
• The data of this stusty implicate NTNG1 in the pathophysiology of schizophrenia and bipolar disorder, but do not support the hypothesis that altered mRNA expression is the mechanism by which genetic variation of NTNG1 may confer disease susceptibility. (PMID:17507910)
• Netrin G1 is not involved in atypical Rett syndrome or in unexplained encephalopathy with epilepsy, but in specific forms to be delineated better in the future. (PMID:17903671)
• Genotype and allele frequencies of single nucleotide polymorphisms on NTNG1 are significantly associated with schizophrenia. (PMID:22227940)
• Our finding nominates the minor G allele of the NTNG1 rs628117 single nucleotide polymorphism as a risk factor for ischemic stroke at least in Armenian population. (PMID:23769687)
• Interaction between the tripartite NGL-1, netrin-G1 and LAR adhesion complex promotes development of excitatory synapses. (PMID:23986473)
• examined the hypothesis that NTNG1 allelic variation contributes to the risk for schizophrenia (PMID:25325217)
• Significant genetic family-based associations were detected between NTNG1 polymorphisms and cocaine dependence. NTNG1 expression in BA10, BA46 and the cerebellum, however, were not significantly associated with any allele or haplotype of this gene. (PMID:28074533)
• A 117-base pair SARS-CoV-2 orf1b sequence matched a sequence in the human genome with 94.6% identity. The sequence was in chromosome 1p within an intronic region of the netrin G1 (NTNG1) gene, implicated in schizophrenia. (PMID:32503821)
• A Genetic Study of Cerebral Atherosclerosis Reveals Novel Associations with NTNG1 and CNOT3. (PMID:34073619)
• CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug. (PMID:36536414)
• Comprehensive analysis of the role of Netrin G1 (NTNG1) in hepatocellular carcinoma cells. (PMID:38101695)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ntng1a	ENSDARG00000014973
danio_rerio	ntng1b	ENSDARG00000073713
mus_musculus	Ntng1	ENSMUSG00000059857
rattus_norvegicus	Ntng1	ENSRNOG00000031136

Paralogs (27): USH2A (ENSG00000042781), LAMC3 (ENSG00000050555), LAMA3 (ENSG00000053747), LAMC2 (ENSG00000058085), NTN1 (ENSG00000065320), NTN4 (ENSG00000074527), ATRN (ENSG00000088812), LAMB4 (ENSG00000091128), LAMB1 (ENSG00000091136), LAMA1 (ENSG00000101680), MEGF8 (ENSG00000105429), MEGF9 (ENSG00000106780), ATRNL1 (ENSG00000107518), LAMA4 (ENSG00000112769), LAMA5 (ENSG00000130702), LAMC1 (ENSG00000135862), NTN5 (ENSG00000142233), HSPG2 (ENSG00000142798), TMEFF2 (ENSG00000144339), NTN3 (ENSG00000162068), EGFLAM (ENSG00000164318), LAMB2 (ENSG00000172037), AGRN (ENSG00000188157), NTNG2 (ENSG00000196358), LAMA2 (ENSG00000196569), LAMB3 (ENSG00000196878), TMEFF1 (ENSG00000241697)

Protein

Protein identifiers

Netrin-G1 — Q9Y2I2 (reviewed: Q9Y2I2)

Alternative names: Laminet-1

All UniProt accessions (2): Q9Y2I2, X5DNW2

UniProt curated annotations — full annotation on UniProt →

Function. Involved in controlling patterning and neuronal circuit formation at the laminar, cellular, subcellular and synaptic levels. Promotes neurite outgrowth of both axons and dendrites.

Subunit / interactions. Interacts with NGL1.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in the thalamus, with very low expression, if any, in other tissues.

Post-translational modifications. N-glycosylated.

Domain organisation. The laminin N-terminal domain mediates 1:1 binding to NGL ligand with sub-micromolar affinity. Three NGL-binding loops mediate discrimination for LRRC4C/NGL1 among other NGLs by binding specifically to its LRR repeats. This specificity drives the sorting of a mixed population of molecules into discrete cell surface subdomains.

Miscellaneous. Mostly expressed in adult brain. Hi expression in Expressed in brain and. Mostly expressed in kidney, also expressed in adult and fetal brain. Some expression in fetal brain.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9Y2I2-3	3, 1A	yes
Q9Y2I2-2	2, 1F
Q9Y2I2-1	1, 1C
Q9Y2I2-4	4, 1D
Q9Y2I2-5	5, 1E
Q9Y2I2-6	6, 1G

RefSeq proteins (11): NP_001106697, NP_001106699, NP_001299617, NP_001317594, NP_001359095, NP_001359096, NP_001359097, NP_001359098, NP_001359099, NP_001359100, NP_055732 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR002049	LE_dom	Domain
IPR008211	Laminin_N	Domain
IPR050440	Laminin/Netrin_ECM	Family
IPR056863	LMN_ATRN_NET-like_EGF	Domain

Pfam: PF00053, PF00055, PF24973

UniProt features (79 total): strand 20, disulfide bond 19, splice variant 9, helix 9, glycosylation site 4, domain 4, sequence conflict 4, turn 3, region of interest 3, signal peptide 1, chain 1, lipid moiety-binding region 1, propeptide 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3ZYJ	X-RAY DIFFRACTION	3.25

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2I2-F1	84.13	0.59

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 510

Disulfide bonds (19): 33–50, 72–92, 80–88, 182–206, 297–306, 299–315, 317–326, 329–354, 364–373, 366–384, 387–396, 399–417, 420–432, 422–438, 440–449, 452–462, 467–480, 474–486, 488–497

Glycosylation sites (4): 133, 320, 406, 433

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins

MSigDB gene sets: 293 (showing top): GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_NEUROGENESIS, GOBP_CELL_CELL_SIGNALING, GOBP_CELL_CELL_ADHESION, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_CELL_JUNCTION_ORGANIZATION, MODULE_379, GOBP_REGULATION_OF_NEURON_MIGRATION, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_NEURON_MIGRATION, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, GOBP_SYNAPTIC_SIGNALING, MODULE_88, GOBP_REGULATION_OF_NEURON_PROJECTION_DEVELOPMENT

GO Biological Process (8): axonogenesis (GO:0007409), regulation of neuron projection development (GO:0010975), modulation of chemical synaptic transmission (GO:0050804), synaptic membrane adhesion (GO:0099560), regulation of neuron projection arborization (GO:0150011), regulation of neuron migration (GO:2001222), nervous system development (GO:0007399), cell differentiation (GO:0030154)

GO Molecular Function (3): cell adhesion molecule binding (GO:0050839), cell-cell adhesion mediator activity (GO:0098632), protein binding (GO:0005515)

GO Cellular Component (7): extracellular region (GO:0005576), plasma membrane (GO:0005886), presynaptic active zone membrane (GO:0048787), side of membrane (GO:0098552), Schaffer collateral - CA1 synapse (GO:0098685), glutamatergic synapse (GO:0098978), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell-cell adhesion	2
membrane	2
synapse	2
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
neuron projection development	1
regulation of plasma membrane bounded cell projection organization	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
synapse organization	1
regulation of cell morphogenesis	1
regulation of cell projection organization	1
neuron projection arborization	1
neuron migration	1
regulation of cell migration	1
system development	1
cellular developmental process	1
protein binding	1
cell adhesion mediator activity	1
binding	1
cell periphery	1
presynaptic membrane	1
presynaptic active zone	1
synaptic membrane	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

2528 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NTNG1	LRRC4C	Q9HCJ2	999
NTNG1	CDKL5	O76039	844
NTNG1	LRRC4	Q9HBW1	799
NTNG1	LRRC4B	Q9NT99	751
NTNG1	MECP2	P51608	673
NTNG1	GLRA2	P23416	669
NTNG1	GPM6B	Q13491	668
NTNG1	GRPR	P30550	659
NTNG1	GDI1	P31150	639
NTNG1	GLUD2	P49448	638
NTNG1	ROBO2	Q9HCK4	603
NTNG1	HCCS	P53701	580
NTNG1	UNC5C	O95185	566
NTNG1	CDH8	P55286	531
NTNG1	IL1RAPL1	Q9NZN1	531

IntAct

11 interactions, top by confidence:

A	B	Type	Score
NTNG1	NUDT16L1	psi-mi:“MI:0915”(physical association)	0.620
NTNG1	LRRC4C	psi-mi:“MI:0407”(direct interaction)	0.620
LRRC4C	NTNG1	psi-mi:“MI:0407”(direct interaction)	0.620
NTNG1	LRRC4	psi-mi:“MI:0407”(direct interaction)	0.440
LRRC4	NTNG1	psi-mi:“MI:0407”(direct interaction)	0.440
NTNG1	RPN1	psi-mi:“MI:0915”(physical association)	0.400
NTNG1	AMY1A	psi-mi:“MI:0914”(association)	0.350
NTNG1	UBA6	psi-mi:“MI:0914”(association)	0.350
NTNG1	SRPX2	psi-mi:“MI:0914”(association)	0.350

BioGRID (105): HSPA6 (Affinity Capture-MS), GAS6 (Affinity Capture-MS), LRRC4C (Affinity Capture-Western), LRRC4C (Reconstituted Complex), NTNG1 (Proximity Label-MS), LRRC4C (Co-crystal Structure), MUC5B (Affinity Capture-MS), NUDT16L1 (Affinity Capture-MS), AMY1C (Affinity Capture-MS), BPIFA1 (Affinity Capture-MS), PGA4 (Affinity Capture-MS), LIPF (Affinity Capture-MS), USO1 (Affinity Capture-MS), PPME1 (Affinity Capture-MS), HDLBP (Affinity Capture-MS)

ESM2 similar proteins: A0A6I8RMG7, A0JP86, A4D0S4, O54890, O70309, P02468, P02469, P05106, P0CY46, P11046, P11047, P13387, P13388, P15215, P15800, P18084, P18563, P18564, P19137, P24043, P25391, P35555, P55268, P80747, P98133, Q07441, Q18823, Q1LVF0, Q1RPR6, Q2KIT5, Q5RB89, Q60675, Q61220, Q61292, Q61526, Q61554, Q61555, Q62918, Q6AYF4, Q6UXH1

Diamond homologs: A0JP86, A2ASQ1, G5ECE3, O00468, O00634, O09118, O15230, O75445, O75882, O95631, P02468, P11047, P15215, P19137, P24043, P25304, P25391, P31696, P34710, P97927, Q00174, Q01635, Q13751, Q13753, Q16363, Q16787, Q18823, Q19981, Q1LVF0, Q24567, Q24568, Q27262, Q2HXW4, Q2QI47, Q5RB89, Q5VV63, Q60675, Q61001, Q61087, Q61092

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
NTNG1	“up-regulates activity”	LRRC4C	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

85 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	54
Likely benign	5
Benign	15

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

3547 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:107324309:T:A	C92S	1.000
1:107324310:G:C	C92S	1.000
1:107324387:T:A	W118R	1.000
1:107324387:T:C	W118R	1.000
1:107324389:G:C	W118C	1.000
1:107324389:G:T	W118C	1.000
1:107324551:G:C	W172C	1.000
1:107324551:G:T	W172C	1.000
1:107324581:C:G	C182W	1.000
1:107324652:G:A	C206Y	1.000
1:107324653:C:G	C206W	1.000
1:107324820:T:C	L262P	1.000
1:107430812:T:A	C384S	1.000
1:107430812:T:C	C384R	1.000
1:107430813:G:A	C384Y	1.000
1:107430813:G:C	C384S	1.000
1:107430814:C:G	C384W	1.000
1:107430821:T:A	C387S	1.000
1:107430822:G:A	C387Y	1.000
1:107430822:G:C	C387S	1.000
1:107430823:T:G	C387W	1.000
1:107430848:T:A	C396S	1.000
1:107430848:T:C	C396R	1.000
1:107430849:G:A	C396Y	1.000
1:107430849:G:C	C396S	1.000
1:107430849:G:T	C396F	1.000
1:107430850:T:G	C396W	1.000
1:107430857:T:A	C399S	1.000
1:107430858:G:C	C399S	1.000
1:107436727:T:A	C440S	1.000

dbSNP variants (sampled 300 via entrez): RS1000012192 (1:107222474 T>C), RS1000015331 (1:107474997 A>T), RS1000018353 (1:107240457 C>T), RS1000026575 (1:107283393 C>G,T), RS1000030157 (1:107333217 A>G), RS1000034719 (1:107313065 G>A), RS1000042553 (1:107409973 C>T), RS1000052186 (1:107431730 A>G), RS1000061495 (1:107162971 G>A,C), RS1000078443 (1:107161262 C>T), RS1000086770 (1:107312795 G>A), RS1000090177 (1:107270258 CTG>C), RS1000102655 (1:107388212 A>T), RS1000109017 (1:107270672 A>G), RS1000111799 (1:107155410 T>C)

Disease associations

OMIM: gene MIM:608818 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
atypical Rett syndrome	Supportive	Autosomal dominant
syndromic intellectual disability	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	AD

Mondo (2): atypical Rett syndrome (MONDO:0017746), syndromic intellectual disability (MONDO:0000508)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs61816456	Efficacy	3	allopurinol

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases expression, decreases expression, affects cotreatment	3
monomethylarsonous acid	affects expression, decreases expression	2
aristolochic acid I	decreases expression	1
sodium arsenite	increases expression	1
tobacco tar	decreases expression	1
rutecarpine	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
2-palmitoylglycerol	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Zoledronic Acid	decreases expression	1
Vorinostat	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Cytarabine	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	decreases expression	1
Aflatoxin B1	decreases methylation	1
Thapsigargin	increases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.